Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II R-DHAP + high-dose methotrexate plus intrathecal rituximab followed by autologous stem cell transplantation for relapsed aggressive B-cell lymphoma with CNS involvement
NL-OMON23427Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Oct 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, methotrexate, cisplatin, cytarabine and dexamethasone in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL), sponsored by HOVON. Primary endpoint: Progression-free survival. Started Oct 2006; status: recruiting.
02
Drugs
rituximabmethotrexatecisplatincytarabinedexamethasone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON23427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23427.